• 1
    Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier B, Lockey R et al. A revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of World Allergy Organization. J Allergy Clin Immunol 2004;113:832836.
  • 2
    Muraro A, Roberts G, Clark A, Eigenmann PA, Halken S, Lack G et al. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy 2007;62:857871.
  • 3
    American Academy of Pediatrics, Committee on School Health. Guidelines for urgent care in school. Pediatrics 1990;86:9991000.
  • 4
    International Collaborative Study of Severe Anaphylaxis. An epidemiologic study of severe anaphylactic and anaphylactoid reactions among hospital patients: methods and overall risks. Epidemiology 1998;9:141146.
  • 5
    Australasian Society of Clinical Immunology and Allergy Inc. (ASCIA). Guidelines for EpiPen prescription. ASCIA Anaphylaxis Working Party 2004. Available online at Last accessed on 20th September 2012
  • 6
    Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; and Joint Council of Allergy, Asthma, and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005;15(Suppl 3):S483S523.
  • 7
    Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF, Bock A, Branum A et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391397.
  • 8
    Walker S, Sheikh A. Managing anaphylaxis: effective emergency and long-term care are necessary. Clin Exp Allergy 2003;33:10151018.
  • 9
    Dhami S, Panesar SS, Rader T, Muraro A, Roberts G, Worm M et al. The acute and long-term management of anaphylaxis: protocol for a systematic review. Clin Transl Allergy 2013;3:14.
  • 10
    International Prospective Register of Systematic Reviews (PROSPERO CRD42013003703.
  • 11
    Agresti A, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 1998;52:119126.
  • 12
    Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev 2008;CD006312.
  • 13
    Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev 2012;CD006312.
  • 14
    Sheikh A, Simons FER, Barbour V, Worth A. Adrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the community. Cochrane Database Syst Rev 2012;8, dOI: 10.1002/14651858.CD008935.pub2
  • 15
    Safdar B, Cone D, Pham K. Subcutaneous epinephrine in the prehospital setting. Prehosp Emerg Care 2000;5:200207.
  • 16
    Simons FE, Roberts J, Gu X, Simons K. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998;101:3337.
  • 17
    Simons FE, Gu X, Simons K. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001;108:871873.
  • 18
    Simons FE, Gu X, Johnston L, Simons K. Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? Pediatrics 2000;106:10401044.
  • 19
    Simons FER, Gu X, Silver N, Simons K. EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis. J Allergy Clin Immunol 2002;109:171175.
  • 20
    Jarvinen K, Sicherer S, Sampson H, Nowak-Wegrzyn A. Use of multiple doses of epinephrine in food-induced anaphylaxis in children. J Allergy Clin Immunol 2008;122:133138.
  • 21
    Soreide E, Buxrud T, Harboe S. Severe anaphylactic reactions outside hospital: etiology, symptoms and treatment. Acta Anaesthesiol Scand 1988;32:339342.
  • 22
    Bock S, Munoz-Furlong A, Sampson H. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001;107:191193.
  • 23
    Bock S, Munoz-Furlong A, Sampson H. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007;119:10161018.
  • 24
    Pumphrey RSH. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000;30:11441150.
    Direct Link:
  • 25
    Pumphrey RH, Gowland H. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007;119:10181019.
  • 26
    Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992;327:380384.
  • 27
    Choo K, Simons FE, Sheikh A. Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2010;65:2051211.
  • 28
    Choo K, Simons FE, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. Cochrane Database Syst Rev 2012;CD007596.
  • 29
    Sheikh A, Ten Broek V, Brown GA, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2007;62:830837.
  • 30
    Sheikh A, Ten BV, Brown GA, Simons FE. H1-antihistamines for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev 2012;CD006160.
  • 31
    Lin RY, Curry A, Pesola GR, Knight RJ, Lee HS, Bakalchuk L et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antihistamines. Ann Emerg Med 2000;36:462468.
  • 32
    Runge J, Martinez JC, Caravati E, Williamson S, Hartsell S. Histamine antihistamines in the treatment of acute allergic reactions. Ann Emerg Med 1992;21:237242.
  • 33
    Ernst ME, Graber MA. Methylxanthine use in anaphylaxis: what does the evidence tell us? Ann Pharmacother 1999;33:10011004.
  • 34
    Choo K, Sheikh A. Action plans for the long-term management of anaphylaxis: systematic review of effectiveness. Clin Exp Allergy 2007;37:10901094.
  • 35
    Nurmatov U, Worth A, Sheikh A. Anaphylaxis management plans for the acute and long-term management of anaphylaxis: a systematic review. J Allergy Clin Immunol 2008;122:353361.
  • 36
    Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012;10:CD008838.
  • 37
    Ross R, Nelson H, Finegold I. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther 2000;22:351358.
  • 38
    Watanabe A. Specific-immunotherapy using Hymenoptera venom: systematic review. Sao Paulo Med J 2010;128:3037.
  • 39
    Hockenhull J, Elremeli M, Cherry MG, Mahon J, Lai M, Darroch J et al. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen for the treatment of bee and wasp venom allergy. Health Technol Assess 2012;16:1110.
  • 40
    Brown S, Wiese M, Blackman K, Heddle R. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003;361:10011006.
  • 41
    Golden D, Valentine M, Kagey-Sobotka A, Lichtenstein L. Regimens of hymenoptera venom immunotherapy. Ann Intern Med 1980;92:620624.
  • 42
    Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157161.
  • 43
    Mosbech H, Malling H, Biering I, Bowadi H, Soborg M, Weeke B et al. Immunotherapy with Yellow Jacket Venom. A comparative study including three different extracts, one adsorbed to Aluminium Hydroxide and two unmodified. Allergy 1986;41:95103.
  • 44
    Müller U, Lanner A, Schmid P, Bischof M, Dreborg S, Hoigné R. A double blind study on immunotherapy with chemically modified honey bee venom: monomethoxy polyethylene glycol-coupled versus crude honey bee venom. Int Arch Allergy Appl Immunol 1985;77:201203.
  • 45
    Müller U, Rabson AR, Bischof M, Lomnitzer R, Dreborg S, Lanner A. A double-blind study comparing glycol-modified honeybee venom and unmodified honeybee venom for immunotherapy. J Allergy Clin Immunol 1987;80:252261.
  • 46
    Oude Elberink J, de Monchy J, van der Heide S, Guyatt H, Dubois A. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002;110:174182.
  • 47
    Oude Elberink J, van der Heide S, Guyatt H, Dubois A. Analysis of the burden of treatment in patients receiving an Epipen for yellow jacket anaphylaxis. J Allergy Clin Immunol 2006;118:174182.
  • 48
    Quercia O, Rafanelli S, Puccinelli P, Stefanini F. The safety of cluster immunotherapy with aluminium hydroxide-adsorbed honey bee venom extract. J Investig Allergol Clin Immunol 2001;11:2733.
  • 49
    Golden D, Kagey-Sobotka A, Valentine M, Lichtenstein L. Prolonged maintenance interval in Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:482484.
  • 50
    Muller U, Thurnheer R, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hypersensitivity. Allergy 1979;34:369378.
  • 51
    Thurnheer U, Muller U, Stoller R, Lanner A, Hoigne R. Venom Immunotherapy in hymenoptera sting allergy. Allergy 1983;38:465475.
  • 52
    Spina J, Mcintyre L, Pulcini J. An intervention to increase high school students compliance with carrying auto-injectable epinephrine: a MASNRN Study. J Sch Nurs 2012;28:230237.
  • 53
    Manassis K. Managing anxiety related to anaphylaxis in childhood: a systematic review. J Allergy (Cairo) 2012;2012:316296.
  • 54
    Habib A. Effect of premedication on early adverse reactions following antivenom use in snakebite: a systematic review and meta-analyses. Drug Saf 2011;34:869880.
  • 55
    De Silva H, Pathmeswaran A, Ranasinha C, Jayamanne S, Samarakoon B, Hittharage A et al. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomized, double-blind, placebo=controlled trial. PLoS Med 2011;8:e1000435.
  • 56
    Tramer M, von Elm E, Loubeyre P, Hauser C. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ 2006;333:675.
  • 57
    Walker S, Sheikh A. Managing anaphylaxis: effective emergency and long-term care are necessary. Clin Exp Allergy 2003;33:10151018.
  • 58
    Ewan PW, Clark AT. Long-term prospective observational study of patients with peanut and nut allergy after participation in a management plan. Lancet 2001;357:111115.
  • 59
    Ewan PW, Clark AT. Efficacy of a management plan based on severity assessment in longitudinal and case-controlled studies of 747 children with nut allergy: proposal for good practice. Clin Exp Allergy 2005;35:751756.
  • 60
    Kapoor S, Roberts G, Bynoe Y, Gaughan M, Habibi P, Lack G. Influence of a multidisciplinary paediatric allergy clinic on parental knowledge and rate of subsequent allergic reactions. Allergy 2004;59:185191.
  • 61
    Kastner M, Harada L, Waserman S. Gaps in anaphylaxis management at the level of physicians, patients, and the community: a systematic review of the literature. Allergy 2010;65:436444.
  • 62
    Papadopoulos NG, Agache I, Bavbek S, Bilo BM, Braido F, Cardona V et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy 2012;2:21.